Processa Pharmaceuticals (PCSA) Other Non-Current Liabilities (2020 - 2023)

Processa Pharmaceuticals (PCSA) has reported Other Non-Current Liabilities for 4 consecutive years, with $189000.0 the latest figure, recorded in Q4 2023.

• For the quarter ending Q4 2023, Other Non-Current Liabilities changed 0.0% year-over-year to $189000.0; the trailing twelve-month figure through Dec 2023 stood at $189000.0 (changed 0.0% YoY), and the FY2023 full-year result was $189000.0, changed 0.0% from the prior year.
• Other Non-Current Liabilities was little changed at $189000.0 in Q4 2023 per PCSA's latest filing, from $189000.0 in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $589000.0 in Q2 2022 and bottomed at $189000.0 in Q4 2022.
• Historically, Other Non-Current Liabilities has averaged $347923.1 across 4 years, with a median of $400000.0 in 2020.
• The sharpest annual moves came in 2022 and 2023: Other Non-Current Liabilities soared 47.25% in 2022, then tumbled 67.91% in 2023.
• Over 4 years, Other Non-Current Liabilities stood at $400000.0 in 2020, then changed by 0.0% to $400000.0 in 2021, then sank by 52.75% to $189000.0 in 2022, then changed by 0.0% to $189000.0 in 2023.
• According to Business Quant data, Other Non-Current Liabilities over the past three periods registered $189000.0, $189000.0, and $189000.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.